Following FDA approval of the first oral GLP-1 for obesity, AACE President Scott D. Isaacs, MD, FACP, FACE, called the Wegovy pill one of the most important developments in endocrinology in 2025, noting that an oral option expands access to effective obesity treatment while requiring careful attention to dosing and tolerability. Learn more by reading the full article on Healio.